Les 10 concurrents psyarxiv.com les plus visités

figshare.com

The animated diagram of titled Resonance with Emergence of Transformation recontextualizes Hartmut Rosa's theory by presenting the four elements—affection, emotion, transformation (here, "formation"), and unpredictability—in a dynamic interplay that highlights the formation of identity. In this diagram, "formation" replaces "transformation" to emphasize how our sense of self and individual character traits are continually shaped through daily interactions with the world, people, and material objects. This diagram aims to underscore that genuine resonance, as Rosa describes, involves deep and lasting connections that fundamentally transform the individual. The diagram illustrates how these resonant experiences, regardless of their duration, leave enduring imprints on the self, fostering true and lasting transformation (illustrated here with an emerging light green sphere that expands). This series of repeated resonant interactions builds upon the individual’s identity, showing that each occurrence of resonance contributes to the ongoing formation and reformation of the self, culminating in a profound and genuine transformation that Rosa describes. This visual representation aims to capture Rosa’s notion of genuine resonance, that is not just a fleeting moment but a continuous process with lasting impacts on personal growth and identity.

sportrxiv.org

the preprint server for sport and exercise science.

jnm.snmjournals.org

Radioimmunotherapy using 225Ac, a highly cytotoxic α-particle emitter, has potential for treating advanced breast cancer, especially human epidermal growth factor receptor 2 (HER2)–positive cases. We use a pretargeted radioimmunotherapy (PRIT) approach consisting of a 3-step intravenous regimen (step 1: bispecific anti-HER2/anti-DOTA antibody; step 2: clearing agent; step 3: 225Ac-radiolabeled Proteus DOTA, or [225Ac]Ac-Pr). Our goal was to establish curative 225Ac-PRIT with high therapeutic indices. Methods: The impact of [225Ac]Ac-Pr specific activity was evaluated in the BT-474 breast xenograft model. We tested the effects of [225Ac]Ac-Pr dosing during PRIT on tumor-targeting efficiency and tissue biodistribution. Using a 225Ac-PRIT regimen consisting of a ratio of 1.19 nmol of bispecific antibody to 0.60–0.66 nmol of [225Ac]Ac-Pr, we evaluated therapy in the BT-474 model and a patient-derived xenograft model. BT-474-tumor–bearing mice were treated with 1 or 2 cycles of 225Ac-PRIT (37 kBq/cycle) separated by 1 wk. A dose escalation study was performed on the BT-474 model to establish an absorbed radiation dose of approximately 40 Gy (relative biological effectiveness [RBE], 5) as a nephrotoxic dose, as no such histologic findings were observed in prior studies at the 20.7-Gy (RBE, 5) renal dose level. Results: In the BT-474 model, 100% (20/20) achieved complete responses and histologic cure in 17 of 20 (85%) of the treated animals. One-cycle and 2-cycle treatments were equally effective. Treatments were well tolerated, with no chronic radiation toxicity documented during necropsy at 175 d. Dosimetry estimates (RBE, 5) per 37 kBq administered for tumors and kidneys were 210 and 3.5 Gy, respectively. In the patient-derived xenograft model, a single 225Ac-PRIT treatment led to 60% (3/5) complete response and prolonged survival (>93 d) versus no treatment (30 d; P = 0.0185). Lastly, a 225Ac-PRIT regimen was identified that induces severe chronic nephrotoxicity (41.4

meduniwien.ac.at

Willkommen an der Medizinischen Universität Wien.